The abstract is read at the publisher; the summary is JClub's.
Mirvetuximab soravtansine, an FRα-targeting antibody-drug conjugate, has regulatory approval for platinum-resistant ovarian cancer, marking a major clinical milestone for FRα-directed therapy.
- Why it matters: FRα is a tumor-associated antigen with limited normal epithelial distribution and overexpression across multiple malignancies, motivating immunotherapies that can exploit it as both a biomarker and therapeutic axis.
- What they did: The review consolidates evidence across FRα-targeting platforms—monoclonal antibodies, antibody-drug conjugates, T-cell–redirecting bispecific engagers, CAR T-cell approaches, biparatopic ADCs, and peptide vaccines—linking mechanisms and clinical outcomes across cancers.
- The result: By integrating translational and clinical insights, it organizes ongoing and established FRα strategies around clinical trials and highlights key development challenges, supporting interpretation of observed outcomes.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.